CTIC
CTI BioPharma Corp. [CTIC] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CTIC Stock Summary
In the News
CTIC Financial details
Company Rating
-
Market Cap
1.2B
Income
-77.01M
Revenue
75.77M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
127
Optionable
No
Shortable
Yes
Earnings
07 Aug 2023
P/E
-15.54
Forward P/E
-
PEG
3.67
P/S
15.83
P/B
-47.21
P/C
-
P/FCF
-14.57
Quick Ratio
1.2
Current Ratio
1.27
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.64
EPS next Y
-
EPS next Q
-
EPS this Y
-28.83%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
8.72%
Revenue last 5Y
15.46%
Revenue Q/Q
14.39%
EPS Q/Q
30.77%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-69%
ROE
474%
ROC
-1.22%
Gross Margin
94%
Oper. Margin
-71%
Profit Margin
-102%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
4.01-9.1
52W High
-
52W Low
-
RSI
-
Rel Volume
0.98
Avg Volume
5.66M
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
0.830633
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-
Company Profile
- Volume Average 5.66M
- Market Capitalization 1.2B
- Employee 127
- CEO Dr. Adam R. Craig M.B.A., M.D., Ph.D.
- Headquarters Seattle,WA,US
- IPO Date 1997-03-21
-
Website
https://www.ctibiopharma.com 
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
